Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

Shares of Eli Lilly ( LLY -2.37%) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S ...